ASTRAZENECA PLC News

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 12 22:16

AstraZeneca | 6-K: Acquisition of Fusion Completed

Jun 5 04:33

25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

Jun 4 22:07

AstraZeneca | 6-K: Block Listing Six Monthly Return

Jun 3 22:31

AstraZeneca | 6-K: Total Voting Rights

Jun 3 22:25

AstraZeneca | 6-K: Tagrisso Plus Chemo Recommended for Approval in EU

Jun 3 18:40

6-K: Dato-DXd Improved OS in Nonsquamous Lung Cancer

May 28 18:16

AstraZeneca | 6-K: AstraZeneca to Deliver $80bn Revenue by 2030

May 21 18:10

AstraZeneca | 6-K: AstraZeneca Plans $1.5 Billion Manufacturing Facility

May 20 18:34

6-K: Supernova Phase Iii Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing Covid-19 in Immunocompromised Patient Population

May 16 18:46

6-K: Transaction by Person Discharging Managerial Responsibilities

May 15 22:10

6-K: AstraZeneca Completes Equity Investment Agreement with Cellectis

May 7 19:34

6-K: Calquence Combination Improved PFS in 1L MCL

May 2 18:53

6-K: Total Voting Rights

May 1 22:29

6-K: Truqap Recommended for EU Breast Cancer Approval

Apr 29 19:22

6-K: Enhertu Improved PFS in HER2-Low and Ultralow

Apr 29 18:52

6-K: Q1 2024 Results

Apr 25 18:29

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 12 01:25

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 11 18:59

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 8 18:17